Сравнение
Lixisenatide vs. Mazdutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
320367-13-3
2259884-03-0
Молекулярная масса
4858.5 g/mol
4790 g/mol
Период полувыведения
3 h
132 h
Последовательность
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteМеханизм действия
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
5
4
из них на людях
5
4
Зафиксированные эффекты
3
4
Открытые противоречия
1
0
Задокументированные нежелательные явления
1
0
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Lixisenatide and Mazdutide?
- Lixisenatide is classified as "Метаболизм", while Mazdutide is classified as "Метаболизм". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lixisenatide or Mazdutide?
- The highest available evidence level is "РКИ на людях" for Lixisenatide and "РКИ на людях" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lixisenatide and Mazdutide in Germany and the United States?
- Германия: Lixisenatide — Рецептурный, Mazdutide — Только для исследований. США: Lixisenatide — Не одобрено, Mazdutide — Только для исследований. These are factual summaries with source and review date on the individual pages.